Globus Medical, Inc. (GMED) AI Stock Analysis

Globus Medical, Inc. develops and markets healthcare solutions for individuals with musculoskeletal disorders worldwide. Its core portfolio includes traditional spinal fusion implants such as pedicle screw, rod, and plating systems, intervertebral spacers, and corpectomy devices. The company also offers motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. Additional offerings encompass interventional pain management solutions for vertebral compression fractures, orthopedic trauma treatments such as fracture plates and intramedullary nails, and hip and knee joint arthroplasty implants. Headquartered in Audubon, Pennsylvania, Globus Medical was founded in 2003 and has 6,000 employees.

Globus Medical expanded its annual revenue from $958.1M in FY2021 to $2.94B in FY2025, representing a 5-year revenue CAGR of 30.1%. Annual revenue growth reached 60.6% in FY2024 and 16.7% in FY2025. Gross margin stood at 67.4% in FY2025, recovering from 58.9% in FY2024, while operating margin rose to 16.3%. Net income increased to $537.9M in FY2025, with EPS of $4.00. For the trailing twelve months ending June 30, 2026, revenue totaled $3.14B with an operating margin of 24.8% and net profit margin of 17.0%. In the latest quarter ended June 30, 2026, quarterly revenue grew 5.9% year-over-year, while quarterly earnings declined 26.2%.

As of June 30, 2026, Globus Medical held $595.1M in cash and short-term investments against total debt of $111.2M, resulting in net cash of $483.9M. Total assets were $5.49B and shareholders' equity reached $4.77B, yielding a debt-to-equity ratio of 0.02 and a current ratio of 4.62. In FY2025, the business generated $753.4M in operating cash flow and $588.8M in free cash flow. Capital expenditures were $164.7M, and the company deployed $300.5M into share buybacks, while share count increased 32.6% over the trailing 5-year period.

At a last close of $76.71, Globus Medical has a market capitalization of $10.30B and an enterprise value of $9.45B. The stock trades at a trailing P/E of 19.7x, below the 24.6x median of its US-listed Healthcare peers. Its forward P/E of 13.9x and EV/EBITDA of 9.9x also sit below the peer medians of 17.3x and 12.0x, respectively. The price-to-sales ratio is 3.3x versus the peer median of 4.1x. Over the past year, GMED returned 31.0%, outpacing the S&P 500 (SPY) return of 16.8%, though its 5-year return of 0.4% lags the benchmark's 83.0% gain.

Wall Street coverage on Globus Medical includes 7 Strong Buy, 3 Buy, and 5 Hold ratings, with 0 Sell recommendations. The mean price target is $100.92, representing 31.6% upside over the last close of $76.71. For the fiscal year ending December 31, 2026, analysts estimate revenue of $3.20B and EPS of $5.00, reflecting 25.6% EPS growth. For FY2027, 13 analysts project revenue of $3.39B and EPS of $5.39. Globus Medical has beaten EPS estimates in each of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Globus Medical, Inc. (GMED). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GMED income statement, GMED balance sheet, GMED key metrics, GMED analyst forecast, GMED chart. See the GMED stock overview for the latest quote and news.